Clinically actionable opportunities associated with PRMT5 regulation of DDR genes have been largely unexplored, although several studies have indicated susceptibility of blood and prostate cancers to ATM inhibitors (16) or irradiation (14). This evidence concerns the gene PRMT5 and Familial prostate cancer.